| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | NSC-87877 | GDSC1000 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |